Literature DB >> 26891627

Stroke vision, aphasia, neglect (VAN) assessment-a novel emergent large vessel occlusion screening tool: pilot study and comparison with current clinical severity indices.

Mohamed S Teleb1, Anna Ver Hage1, Jaqueline Carter1, Mahesh V Jayaraman2, Ryan A McTaggart2.   

Abstract

BACKGROUND: Identification of emergent large vessel occlusion (ELVO) stroke has become increasingly important with the recent publications of favorable acute stroke thrombectomy trials. Multiple screening tools exist but the length of the examination and the false positive rate range from good to adequate. A screening tool was designed and tested in the emergency department using nurse responders without a scoring system.
METHODS: The vision, aphasia, and neglect (VAN) screening tool was designed to quickly assess functional neurovascular anatomy. While objective, there is no need to calculate or score with VAN. After training participating nurses to use it, VAN was used as an ELVO screen for all stroke patients on arrival to our emergency room before physician evaluation and CT scan.
RESULTS: There were 62 consecutive code stroke activations during the pilot study. 19 (31%) of the patients were VAN positive and 24 (39%) had a National Institutes of Health Stroke Scale (NIHSS) score of ≥6. All 14 patients with ELVO were either VAN positive or assigned a NIHSS score ≥6. While both clinical severity thresholds had 100% sensitivity, VAN was more specific (90% vs 74% for NIHSS ≥6). Similarly, while VAN and NIHSS ≥6 had 100% negative predictive value, VAN had a 74% positive predictive value while NIHSS ≥6 had only a 58% positive predictive value.
CONCLUSIONS: The VAN screening tool accurately identified ELVO patients and outperformed a NIHSS ≥6 severity threshold and may best allow clinical teams to expedite care and mobilize resources for ELVO patients. A larger study to both validate this screening tool and compare with others is warranted. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Economics; Stroke; Thrombectomy

Mesh:

Year:  2016        PMID: 26891627      PMCID: PMC5284468          DOI: 10.1136/neurintsurg-2015-012131

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


Introduction

Several recent clinical trials1–5 have established embolectomy as the standard of care6 7 for patients with severe stroke who present with emergent large vessel occlusion (ELVO). Unfortunately, inefficient prehospital and early hospital care can delay time to embolectomy (groin puncture), the treatment effect for which is time dependent.8 Our systems of care need to be designed to match the disease we are treating so that patients both get to the right place the first time and ELVO team activation is early and appropriate. Effective and efficient prehospital triage of patients with ELVO is now the holy grail of stroke care delivery innovation. Several stroke assessment tools exist, including the 3 item stroke scale (3I-SS),9 Cincinnati Prehospital Stroke Severity Scale (CPSSS),10 National Institutes of Health Stroke Scale (NIHSS),11 face, arm, speech test (FAST),12 Los Angeles Motor Scale (LAMS),13 legs, eyes, gaze, speech (Texas Stroke Intervention Prehospital Stroke Severity Scale) (LEGS),14 Melbourne Ambulance Stroke Screen (MASS),15 Medic Prehospital Assessment for Code Stroke (Med PACS),15 Ontario Prehospital Stroke Screening (OPSS),16 Rapid Arterial oCclusion Evaluation Scale (RACE),17 and Recognition Of Stroke In the Emergency Room (ROSIER),15 some of which (3I-SS,9 CPSSS,10 LAMS,13 LEGS,14 RACE,17 or severe hemiparesis18) have been used to specifically screen for ELVO but with limitations. For example, the RACE17 scoring system is cumbersome for emergency medical technicians and nurses, takes almost as long as the NIHSS, and requires the user to calculate a score. The 3I-SS,9 CPSS,10 LAMS,13 and RACE17 scores require the user to remember the test items; the name does not trigger testing or next steps. Using LAMS13 or a single deficit screen such as severe hemiparesis18 is a more simple approach but has somewhat limited sensitivity and specificity. Vision, aphasia, and neglect (VAN) is a novel ELVO screening tool we developed to assess functional neurovascular anatomy. It is quick, reproducible, easy to remember and, while objective, requires no score calculations. We tested the ability of VAN to identify ELVO patients presenting to our center and compared it with an NIHSS threshold of ≥6.

Methods

Training

Our emergency room triage nurses, all of whom are NIHSS certified, were trained in how to perform the VAN assessment screen (table 1) during a 2 h training session. The training session included how to perform VAN, including visual field testing, gaze assessment, aphasia testing, and neglect testing, with simultaneous stimuli. They also were briefly informed of why early stroke thrombectomy is so important for patient outcome and emphasized the number needed to treat versus other emergencies in the emergency department, such as ST elevation myocardial infarction (STEMI). Brain and vascular anatomy, as it relates to VAN, was also taught. Functional anatomy of the cortex, motor homunculous, and internal capsule were reviewed. Lacunar syndromes and why they usually do not have cortical symptoms based on anatomy was also emphasized. Lastly, multiple examples of VAN negative and VAN positive patients were presented, including a pure lacunar patient with an NIHSS score of 12 for face, arm, and leg weakness with dysarthria but no aphasia, vision disturbance, or neglect, with follow-up imaging. Other patient examples included sensory neglect, gaze preference, pure expressive and receptive aphasia, and visual field cut.
Table 1

Vision, aphasia, neglect emergent large vessel occlusion screening tool

Stroke VAN
How weak is the patient?Raise both arms up□ Mild (minor drift)
□ Moderate (severe drift—touches or nearly touches ground)
 □ Severe (flaccid or no antigravity)
□ Patient shows no weakness. Patient is VAN negative
(exceptions are confused or comatose patients with dizziness, focal findings, or no reason for their altered mental status then basilar artery thrombus must be considered; CTA is warranted)
Visual disturbance□ Field cut (which side) (4 quadrants)
□ Double vision (ask patient to look to right then left; evaluate for uneven eyes)
 □ Blind new onset
□ None
Aphasia□ Expressive (inability to speak or paraphasic errors); do not count slurring of words (repeat and name 2 objects)
□ Receptive (not understanding or following commands) (close eyes, make fist)
□ Mixed
□ None
Neglect□ Forced gaze or inability to track to one side
□ Unable to feel both sides at the same time, or unable to identify own arm
□ Ignoring one side
□ None

Patient must have weakness plus one or all of the V, A, or N to be VAN positive.

VAN positive patients had 100% sensitivity, 90% specificity, positive predictive value 74%, and negative predictive value 100% for detecting large vessel occlusion.

CTA, CT angiography; VAN, vision, aphasia, and neglect.

Vision, aphasia, neglect emergent large vessel occlusion screening tool Patient must have weakness plus one or all of the V, A, or N to be VAN positive. VAN positive patients had 100% sensitivity, 90% specificity, positive predictive value 74%, and negative predictive value 100% for detecting large vessel occlusion. CTA, CT angiography; VAN, vision, aphasia, and neglect. After the training was completed, the chair of medicine and chief medical officer approved the pilot quality control study due to our prolonged door to puncture times. A formal institutional review board protocol was approved after quality assurance data showed study feasibility and improved process time. For VAN positive patients, nurses were instructed to both obtain CT angiography (CTA) at the time of the initial non-contrast CT (NCCT) and activate the endovascular stroke team. If CTA confirmed an ELVO, the patient was triaged to the endovascular suite when the team was ready. Intravenous tissue plasminogen activator (tPA) candidacy for all patients was determined by the stroke team either at CT scan or immediately thereafter. Hemorrhages were excluded and treated appropriately after NCCT. All VAN negative patients also had acute vascular vessel imaging. VAN negative patients received CTA or an MR angiogram of head and neck after administration of tPA. See figure 1 for our stroke triage process before and after the VAN study protocol.
Figure 1

Stroke process before and after the VAN protocol was initiated. CTA, CT angiography; tPa, tissue plasminogen activator; VAN, vision, aphasia, neglect.

Stroke process before and after the VAN protocol was initiated. CTA, CT angiography; tPa, tissue plasminogen activator; VAN, vision, aphasia, neglect.

Performing the VAN examination

The initial and sine qua non of the VAN examination is to conduct a motor weakness assessment (table 1). Patients are asked to raise both arms up and hold them up for 10 s. If the patient has mild drift, severe weakness, or paralysis, the assessment continues. In their absence, the patient is VAN negative and the assessment ends. If weakness (mild drift, severe weakness, or paralysis) is observed, the VAN assessments are carried out (table 1). If the patient has weakness and any other positive finding among the vision, aphasia, or neglect category, they are considered VAN positive. While forced gaze to one side might be considered a visual finding among users, we included it within the neglect category. Table 2 compares elements of the VAN ELVO screening with others that have been published.
Table 2

Comparison of aspect of the vision, aphasia, neglect emergent large vessel occlusion screening with other screening tools

ToolRACELEGSLAMSHemiparesisVAN3I-SSCPSSS
Aspect tested
Arm weaknessYesNoYesYesYesYesYes
Face weaknessYesNoYesNoNoNoNo
Leg weaknessYesYesNoYesNoYesNo
GazeYesYesNoNoYesYesYes
Visual field lossYesYesNoNoYesNoNo
NeglectYesNoNoNoYesNoNo
Aphasia/speechYesYesNoNoYesNoYes

3I-SS, 3 item stroke scale; CPSSS, Cincinnati Prehospital Stroke Severity Scale; LAMS, Los Angeles Motor Scale; LEGS, legs, eyes, gaze, speech (Texas Stroke Intervention Prehospital Stroke Severity Scale); RACE, Rapid Arterial oCclusion Evaluation Scale; VAN, vision, aphasia, neglect.

Comparison of aspect of the vision, aphasia, neglect emergent large vessel occlusion screening with other screening tools 3I-SS, 3 item stroke scale; CPSSS, Cincinnati Prehospital Stroke Severity Scale; LAMS, Los Angeles Motor Scale; LEGS, legs, eyes, gaze, speech (Texas Stroke Intervention Prehospital Stroke Severity Scale); RACE, Rapid Arterial oCclusion Evaluation Scale; VAN, vision, aphasia, neglect.

Analysis

The VAN status of patient was used to compare sensitivity, specificity, positive predictive value, negative predictive value, and accuracy to CTA confirmed ELVO. The same analysis was done using the new guideline recommended (NIHSS of 6). ELVO was defined as thromboembolic occlusion of an M1 segment of the middle cerebral artery (MCA), internal carotid artery, basilar artery, or M2 segment for which embolectomy was considered.

Results

Sixty-two acute stroke codes were activated during the screening period: 19 were VAN positive and 24 had an NIHSS score of ≥6. The average NIHSS of a VAN positive patient was 18 (range 2–28) and the average for a VAN negative patient was 2 (range 0–7; n=9 had an NIHSS score of 0, n=7 NIHSS 1, n=8 NIHSS 2, n=1 NIHSS 3, n=6 NIHSS 4, n=5 NIHSS 5, n=6 NIHSS 6, and n=1 NIHSS 7). Fourteen ELVO patients were considered for embolectomy. All were VAN positive and had a NIHSS score of ≥6. The following embolic occlusions were identified on CTA: 10 M1 MCA (4 left and 6 right), 2 top of basilar into P1 of the posterior cerebral artery (1 right, 1 left), 1 ICA, and 1 M2 MCA occlusion. Thirty per cent of stroke codes during this period had no weakness, and the VAN screen was completed in 15 s. The average time from symptom onset to stroke code activation and VAN examination was 2 h during this study period (range 40 min to 5 h 25 min). Table 3 lists the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the VAN screening tool. No patient that was VAN negative or determined to have NIHSS <6 had an ELVO (both had 100% negative predictive value). However, VAN had 90% specificity versus 74% for NIHSS.
Table 3

Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of vision, aphasia, neglect and National Institutes of Health Stroke Scale for emergent large vessel occlusion

Large artery clotNo large artery clot
VAN+14519 Total VAN+
VAN−04343 Total VAN−
14 Large artery clot48 No large artery clot
Large artery clotNo large artery clot
NIHSS ≥6141024 Total
NIHSS <603838 Total
14 Large artery clot48 No large artery clot

Positive predictive value of VAN=14/19=74%; sensitivity=14/14=100%.

Positive predictive value of NIHSS=14/24=58%; sensitivity=14/14=100%.

Negative predictive value of VAN=43/43=100%; specificity=43/48=90%.

Negative predictive value of NIHSS=38/38=100%; specificity=38/48=79%.

Accuracy VAN=57/62=92%.

Accuracy NIHSS=52/62=84%.

In addition, the goal of the quality study was to access average door to needle times. Our average time before implementation of VAN was 2 h 40 min. The time was reduced to 1 h 25 min when the VAN protocol was employed.

NIHSS, National Institutes of Health Stroke Scale; VAN, vision, aphasia, and neglect.

Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of vision, aphasia, neglect and National Institutes of Health Stroke Scale for emergent large vessel occlusion Positive predictive value of VAN=14/19=74%; sensitivity=14/14=100%. Positive predictive value of NIHSS=14/24=58%; sensitivity=14/14=100%. Negative predictive value of VAN=43/43=100%; specificity=43/48=90%. Negative predictive value of NIHSS=38/38=100%; specificity=38/48=79%. Accuracy VAN=57/62=92%. Accuracy NIHSS=52/62=84%. In addition, the goal of the quality study was to access average door to needle times. Our average time before implementation of VAN was 2 h 40 min. The time was reduced to 1 h 25 min when the VAN protocol was employed. NIHSS, National Institutes of Health Stroke Scale; VAN, vision, aphasia, and neglect. There were five patients who were VAN positive without ELVO (false positive): one patient had multiple distal MCA embolic strokes, another had hypoxia with global weakness and left visual field cut, a third had seizure secondary to an old cortical arteriovenous malformation resection, a fourth had conversion reaction, and one had complex migraine. Unfortunately, these were all stroke mimics except for the patient with the multiple distal emboli in the MCA territory. The interobserver reliability of VAN between the trained nurses and stroke physician was 100%.

Discussion

This study demonstrated that VAN is an effective clinical assessment tool by nurses who underwent a 2 h training session to determine the likelihood of a severe stroke caused by an ELVO. VAN captured all patients that were considered for embolectomy (100% sensitivity) and only five VAN positive patients were found to not harbor an ELVO (90% specificity) with 80% (4/5) being stroke mimics. Furthermore, VAN was easily taught and adopted by nurses in our emergency room and outperformed an NIHSS threshold used by physicians in the emergency room. Because the decay in the treatment effect of embolectomy is profound, earlier treatment is much better, and the ability to use VAN for either pre-hospital or in-hospital triage may be critical to improving ELVO outcome. While we used VAN as a screening tool in our emergency room we would like to see it used as a prehospital triage tool for ELVO, similar to the way the 3I-SS,9 LAMS,13 RACE,17 LEGS,14 and severe hemiparesis18 screening tools have been tested and utilized (table 4). Derived from predictive items within the NIHSS, RACE, not surprisingly, had a similar ability to identify an LVO as the NIHSS.17 However, in common with the NIHSS, it may be both too cumbersome to administer in the field and have imperfect accuracy. While much easier to employ and also predictive of LVO, LAMS13 and 3I-SS9 have been criticized because they may not assess those cortical deficits most predictive of LVO: LAMS13 because too few cortical signs are tested and 3I-SS9 because it was not derived from the NIHSS15. The severe hemiparesis score may have value in the field but this was a small and select cohort of patients that only had this severe hemiparesis so it may not be applicable to all stroke comers. VAN, like 3I-SS, is not completely derived from the NIHSS but does test more cortical functions than both the 3I-SS and LAMS yet retains ease of use. Like LAMS, severe hemiparesis, and 3I-SS, it puts motor deficit as the central feature but only makes you assess cortical symptoms if weakness exists, unlike RACE, LEGS, and CPSSS, which force the user to conduct an entire examination every time. In our study, 30% of stroke codes had no focal motor weakness and the VAN screen took only 15 s. VAN is currently being evaluated by emergency medical services in the field in another small pilot study. Larger numbers as well as interobserver reliability of emergency medical services with nurses and physicians is needed.
Table 4

Emergent large vessel occlusion screening to comparisons

RACELEGSLAMSHemiparesisVAN3I-SSCPSSS
Need to calculate scoreYesYesYesNoNoYesYes
No of tests64311–433–4
Length of exam 1–7 (7 is longest)7641235
Positive predictive value (%)42607474
Sensitivity (%)85698127–48multiple etiologies analyzed1006783
Negative predictive value (%)9486Could not be calculated10089
Specificity (%)688189909240
TypeProspectiveProspectiveRetroRetroProspectiveProspectiveRetro
Total No of patients analyzed3571811194562171303

3I-SS, 3 item stroke scale; CPSSS, Cincinnati Prehospital Stroke Severity Scale; LAMS, Los Angeles Motor Scale; LEGS, legs, eyes, gaze, speech (Texas Stroke Intervention Prehospital Stroke Severity Scale); RACE, Rapid Arterial oCclusion Evaluation Scale; Retro, retrospective; VAN, vision, aphasia, neglect.

Emergent large vessel occlusion screening to comparisons 3I-SS, 3 item stroke scale; CPSSS, Cincinnati Prehospital Stroke Severity Scale; LAMS, Los Angeles Motor Scale; LEGS, legs, eyes, gaze, speech (Texas Stroke Intervention Prehospital Stroke Severity Scale); RACE, Rapid Arterial oCclusion Evaluation Scale; Retro, retrospective; VAN, vision, aphasia, neglect. In summary, VAN tests multiple cortical divisions of the MCA while always including motor as its central feature. It is always positive when two divisions/deficits are identified with no calculations. There is no need to finish more examinations after two divisions/deficits are identified. VAN uses the best features of previous scales into one tool. Figure 2 shows areas tested for VAN and other LVO screening tools as per area of brain tested. This figure is used in VAN training.
Figure 2

Large vessel occlusion screening tools—brain view. 3I-SS, 3 item stroke scale; CPSSS, Cincinnati Prehospital Stroke Severity Scale; LAMS, Los Angeles Motor Scale; LEGS, legs, eyes, gaze, speech (Texas Stroke Intervention Prehospital Stroke Severity Scale); RACE, Rapid Arterial oCclusion Evaluation Scale; VAN, vision, aphasia, neglect.

Large vessel occlusion screening tools—brain view. 3I-SS, 3 item stroke scale; CPSSS, Cincinnati Prehospital Stroke Severity Scale; LAMS, Los Angeles Motor Scale; LEGS, legs, eyes, gaze, speech (Texas Stroke Intervention Prehospital Stroke Severity Scale); RACE, Rapid Arterial oCclusion Evaluation Scale; VAN, vision, aphasia, neglect. VAN has a number of clinical applications. It can be used in the field by emergency medical services for the pre-notification and activation of code stroke and ELVO teams. Furthermore, it could be used as a screen (by emergency medical services or emergency room triage teams) to determine which patients require CTA at the time of their initial NCCT. Finally, it could perhaps be best used as a screening tool with which to determine the appropriate patients to maintain in CT until all treatment decisions are made and initiated. This latter use should improve door to needle times for tPA and door to puncture times for embolectomy, as all downstream stroke processes rely on the results of the initial CT and CTA scans. The strengths of this study include the fact that the VAN screen was prospectively applied to all stroke codes coming to our emergency room and was compared with a NIHSS threshold of ≥6 which has been suggested as the embolectomy candidacy threshold.7 Furthermore, VAN was easily taught and employed. The mnemonic triggers the examination steps and no calculations are required. A weakness of our study is that it was a single center study of 62 stroke code activations and we may be over-estimating the accuracy of this screening tool. We may have also underestimated the number of clots lysed before vessel imaging for VAN negative patients due to vessel imaging being conducted after administration of tPA. In addition, making a comparison with a similar screening instrument would strengthen our study considerably. However, training the staff to use two scores may confound the ability to assess their utility independently—users may mix the test items. Our study only assessed arm weakness but this is in line with the design of the LAMS and CPSS which were expected to be performed as a seated examination.10 13 Our highly trained nurse to stroke physician interobserver reliability of 100% can be due to the small number of cases. It could also be due to having three levels of freedom with no exact scoring of VAN, allowing a person to miss one item but identify another, and the outcome of VAN positive would not change. In addition to this, the exact degree of weakness was also not scored. In conclusion, in this prospective small pilot study of code stroke patients, the VAN screening tool was easily taught and adopted, accurately identified patients with ELVO, outperformed a NIHSS threshold, and resulted in early activation of the ELVO team so that door to groin puncture times were improved. Further studies should compare VAN with other prehospital ELVO screens (3P-SS, LAMS, RACE, severe hemiparesis) and quantify the impact on door to needle time and accuracy of ELVO team activation. In addition, larger numbers as well as interobserver reliability of emergency medical services with nurses and physicians is also needed.
  16 in total

1.  Severe hemiparesis as a prehospital tool to triage stroke severity: a pilot study to assess diagnostic accuracy and treatment times.

Authors:  Rishi Gupta; Marissa Manuel; Kumiko Owada; Samish Dhungana; Leslie Busby; Brenda A Glenn; Debbie Brown; Susan A Zimmermann; Christopher Horn; Dustin Rochestie; Joseph T Hormes; Andrew K Johnson; Ahmad Khaldi
Journal:  J Neurointerv Surg       Date:  2015-08-14       Impact factor: 5.836

2.  Embolectomy for stroke with emergent large vessel occlusion (ELVO): report of the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery.

Authors:  Mahesh V Jayaraman; M Shazam Hussain; Todd Abruzzo; Barbara Albani; Felipe C Albuquerque; Michael J Alexander; Sameer A Ansari; Adam S Arthur; Blaise Baxter; Ketan R Bulsara; Michael Chen; Josser E Delgado Almandoz; Josser A Delgado-Almandoz; Justin F Fraser; Don V Heck; Steven W Hetts; Michael Kelly; Seon-Kyu Lee; Thabele Leslie-Mawzi; Ryan A McTaggart; Philip M Meyers; Charles Prestigiacomo; G Lee Pride; Athos Patsalides; Robert M Starke; Robert W Tarr; Don Frei; Peter Rasmussen
Journal:  J Neurointerv Surg       Date:  2015-03-12       Impact factor: 5.836

3.  Design and validation of a prehospital scale to predict stroke severity: Cincinnati Prehospital Stroke Severity Scale.

Authors:  Brian S Katz; Jason T McMullan; Heidi Sucharew; Opeolu Adeoye; Joseph P Broderick
Journal:  Stroke       Date:  2015-04-21       Impact factor: 7.914

4.  Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.

Authors:  Jeffrey L Saver; Mayank Goyal; Alain Bonafe; Hans-Christoph Diener; Elad I Levy; Vitor M Pereira; Gregory W Albers; Christophe Cognard; David J Cohen; Werner Hacke; Olav Jansen; Tudor G Jovin; Heinrich P Mattle; Raul G Nogueira; Adnan H Siddiqui; Dileep R Yavagal; Blaise W Baxter; Thomas G Devlin; Demetrius K Lopes; Vivek K Reddy; Richard du Mesnil de Rochemont; Oliver C Singer; Reza Jahan
Journal:  N Engl J Med       Date:  2015-04-17       Impact factor: 91.245

5.  Endovascular therapy for ischemic stroke with perfusion-imaging selection.

Authors:  Bruce C V Campbell; Peter J Mitchell; Timothy J Kleinig; Helen M Dewey; Leonid Churilov; Nawaf Yassi; Bernard Yan; Richard J Dowling; Mark W Parsons; Thomas J Oxley; Teddy Y Wu; Mark Brooks; Marion A Simpson; Ferdinand Miteff; Christopher R Levi; Martin Krause; Timothy J Harrington; Kenneth C Faulder; Brendan S Steinfort; Miriam Priglinger; Timothy Ang; Rebecca Scroop; P Alan Barber; Ben McGuinness; Tissa Wijeratne; Thanh G Phan; Winston Chong; Ronil V Chandra; Christopher F Bladin; Monica Badve; Henry Rice; Laetitia de Villiers; Henry Ma; Patricia M Desmond; Geoffrey A Donnan; Stephen M Davis
Journal:  N Engl J Med       Date:  2015-02-11       Impact factor: 91.245

6.  A randomized trial of intraarterial treatment for acute ischemic stroke.

Authors:  Olvert A Berkhemer; Puck S S Fransen; Debbie Beumer; Lucie A van den Berg; Hester F Lingsma; Albert J Yoo; Wouter J Schonewille; Jan Albert Vos; Paul J Nederkoorn; Marieke J H Wermer; Marianne A A van Walderveen; Julie Staals; Jeannette Hofmeijer; Jacques A van Oostayen; Geert J Lycklama à Nijeholt; Jelis Boiten; Patrick A Brouwer; Bart J Emmer; Sebastiaan F de Bruijn; Lukas C van Dijk; L Jaap Kappelle; Rob H Lo; Ewoud J van Dijk; Joost de Vries; Paul L M de Kort; Willem Jan J van Rooij; Jan S P van den Berg; Boudewijn A A M van Hasselt; Leo A M Aerden; René J Dallinga; Marieke C Visser; Joseph C J Bot; Patrick C Vroomen; Omid Eshghi; Tobien H C M L Schreuder; Roel J J Heijboer; Koos Keizer; Alexander V Tielbeek; Heleen M den Hertog; Dick G Gerrits; Renske M van den Berg-Vos; Giorgos B Karas; Ewout W Steyerberg; H Zwenneke Flach; Henk A Marquering; Marieke E S Sprengers; Sjoerd F M Jenniskens; Ludo F M Beenen; René van den Berg; Peter J Koudstaal; Wim H van Zwam; Yvo B W E M Roos; Aad van der Lugt; Robert J van Oostenbrugge; Charles B L M Majoie; Diederik W J Dippel
Journal:  N Engl J Med       Date:  2014-12-17       Impact factor: 91.245

7.  Design and validation of a prehospital stroke scale to predict large arterial occlusion: the rapid arterial occlusion evaluation scale.

Authors:  Natalia Pérez de la Ossa; David Carrera; Montse Gorchs; Marisol Querol; Mònica Millán; Meritxell Gomis; Laura Dorado; Elena López-Cancio; María Hernández-Pérez; Vicente Chicharro; Xavier Escalada; Xavier Jiménez; Antoni Dávalos
Journal:  Stroke       Date:  2013-11-26       Impact factor: 7.914

8.  Diagnostic accuracy of stroke referrals from primary care, emergency room physicians, and ambulance staff using the face arm speech test.

Authors:  Joseph Harbison; Omar Hossain; Damian Jenkinson; John Davis; Stephen J Louw; Gary A Ford
Journal:  Stroke       Date:  2003-01       Impact factor: 7.914

9.  A brief prehospital stroke severity scale identifies ischemic stroke patients harboring persisting large arterial occlusions.

Authors:  Bijen Nazliel; Sidney Starkman; David S Liebeskind; Bruce Ovbiagele; Doojin Kim; Nerses Sanossian; Latisha Ali; Brian Buck; Pablo Villablanca; Fernando Vinuela; Gary Duckwiler; Reza Jahan; Jeffrey L Saver
Journal:  Stroke       Date:  2008-06-12       Impact factor: 7.914

10.  2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.

Authors:  William J Powers; Colin P Derdeyn; José Biller; Christopher S Coffey; Brian L Hoh; Edward C Jauch; Karen C Johnston; S Claiborne Johnston; Alexander A Khalessi; Chelsea S Kidwell; James F Meschia; Bruce Ovbiagele; Dileep R Yavagal
Journal:  Stroke       Date:  2015-06-29       Impact factor: 10.170

View more
  34 in total

1.  Leukoaraiosis Attenuates Diagnostic Accuracy of Large-Vessel Occlusion Scales.

Authors:  Y Mayasi; R P Goddeau; M Moonis; B Silver; A H Jun-O'Connell; A S Puri; N Henninger
Journal:  AJNR Am J Neuroradiol       Date:  2017-11-23       Impact factor: 3.825

2.  Association of a Primary Stroke Center Protocol for Suspected Stroke by Large-Vessel Occlusion With Efficiency of Care and Patient Outcomes.

Authors:  Ryan A McTaggart; Shadi Yaghi; Shawna M Cutting; Morgan Hemendinger; Grayson L Baird; Richard A Haas; Karen L Furie; Mahesh V Jayaraman
Journal:  JAMA Neurol       Date:  2017-07-01       Impact factor: 18.302

3.  Utilization of Emergent Neuroimaging for Thrombolysis-Eligible Stroke Patients.

Authors:  Nerses Sanossian; Katherine A Fu; David S Liebeskind; Sidney Starkman; Scott Hamilton; J Pablo Villablanca; Adrian M Burgos; Robin Conwit; Jeffrey L Saver
Journal:  J Neuroimaging       Date:  2016-06-14       Impact factor: 2.486

Review 4.  Prehospital Prediction of Large Vessel Occlusion in Suspected Stroke Patients.

Authors:  Kevin J Keenan; Charles Kircher; Jason T McMullan
Journal:  Curr Atheroscler Rep       Date:  2018-05-21       Impact factor: 5.113

Review 5.  Improving Regional Stroke Systems of Care.

Authors:  Melissa S Eng; Anand V Patel; Richard B Libman; Paul Wright; Jeffrey M Katz
Journal:  Curr Atheroscler Rep       Date:  2017-10-24       Impact factor: 5.113

Review 6.  Unresolved Issues in Thrombectomy.

Authors:  Mahesh V Jayaraman; Ryan A McTaggart; Mayank Goyal
Journal:  Curr Neurol Neurosci Rep       Date:  2017-09       Impact factor: 5.081

7.  Risk Factors for Acute Ischemic Stroke Caused by Anterior Large Vessel Occlusion.

Authors:  Philipp Hendrix; Nelson Sofoluke; Matthew D Adams; Saran Kunaprayoon; Ramin Zand; Amy N Kolinovsky; Thomas N Person; Mudit Gupta; Oded Goren; Clemens M Schirmer; Natalia S Rost; James E Faber; Christoph J Griessenauer
Journal:  Stroke       Date:  2019-05       Impact factor: 7.914

8.  Validation of Stroke Network of Wisconsin Scale at Aurora Health Care System.

Authors:  Kessarin Panichpisal; Maharaj Singh; Adil Chohan; Paul Vilar; Reji Babygirija; Mary Hook; Sharon Matyas; Nathaniel Kojis; Rehan Sajjad; Thomas Wolfe; Amin Kassam; Richard Adam Rovin
Journal:  J Vasc Interv Neurol       Date:  2018-11

9.  Field Assessment Stroke Triage for Emergency Destination: A Simple and Accurate Prehospital Scale to Detect Large Vessel Occlusion Strokes.

Authors:  Fabricio O Lima; Gisele S Silva; Karen L Furie; Michael R Frankel; Michael H Lev; Érica C S Camargo; Diogo C Haussen; Aneesh B Singhal; Walter J Koroshetz; Wade S Smith; Raul G Nogueira
Journal:  Stroke       Date:  2016-06-30       Impact factor: 7.914

10.  Los Angeles Motor Scale to Identify Large Vessel Occlusion: Prehospital Validation and Comparison With Other Screens.

Authors:  Ali Reza Noorian; Nerses Sanossian; Kristina Shkirkova; David S Liebeskind; Marc Eckstein; Samuel J Stratton; Franklin D Pratt; Robin Conwit; Fiona Chatfield; Latisha K Sharma; Lucas Restrepo; Miguel Valdes-Sueiras; May Kim-Tenser; Sidney Starkman; Jeffrey L Saver
Journal:  Stroke       Date:  2018-02-19       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.